Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-t5tsf Total loading time: 0 Render date: 2024-11-10T09:05:17.493Z Has data issue: false hasContentIssue false

Chapter 12 - Psychopharmacology in Prader-Willi Syndrome

Published online by Cambridge University Press:  26 May 2022

By
Deepan Singh ,
Emily Mozdzer  and
Aaron Pinkhasov
Edited by
Deepan Singh
Deepan Singh
Affiliation:
Maimonides Medical Center in Brooklyn
Get access

Summary

Psychopharmacological interventions for the management of the neuro-behavioral manifestations of PWS that have been described throughout the book are the main focus of this particular chapter. A majority of patients with PWS are on one or more psychiatric medications by the time they reach adulthood. Patients with PWS are uniquely vulnerable to psychiatric illness and require a thorough assessment and diagnosis in order to receive appropriate treatment. This chapter outlines the main classes of medication that have been or, in our opinion, ought to be utilized in patients with PWS. We specifically address their common indications, side effects, and dosage recommendations, among other characteristics. Additionally, the complex phenomenon of drug–drug interactions is discussed in some detail, due to the high incidence of “polypharmacy” in PWS. We recognize that a significant portion of caregiver burden is attributable to neuro-behavioral symptoms and endeavor to provide the information necessary to guide providers in addressing that.

Keywords

psychopharmacologyantipsychoticsantidepressantsmood stabilizersbenzodiazepinespsychotropic medicationsdrug–drug interactionspolypharmacystimulants
Type
Chapter
Information
Neuro-behavioral Manifestations of Prader-Willi Syndrome
A Guide for Clinicians and Caregivers
 , pp. 116 - 144
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Matesevac, L, Bohonowych, J, Roof, E, Dykens, E, Miller, J, McCandless, S, et al. PATH for PWS Study 2021 Update: A non-interventional, observational, natural history study of serious medical events in Prader-Willi syndrome. 2021.Google Scholar
Montes, AS, Osann, KE, Gold, JA, Tamura, RN, Driscoll, DJ, Butler, MG, et al. Genetic subtype-phenotype analysis of growth hormone treatment on psychiatric behavior in Prader-Willi syndrome. Genes (Basel) 2020;11(11):1250. doi: 10.3390/genes11111250Google Scholar
Reddy, LA, Pfeiffer, SI. Behavioral and emotional symptoms of children and adolescents with Prader-Willi Syndrome. J Autism Dev Disord 2007;37(5):830–9.CrossRefGoogle ScholarPubMed
Butler, MG, Manzardo, AM, Forster, JL. Prader-Willi syndrome: Clinical genetics and diagnostic aspects with treatment approaches. Curr Pediatr Rev 2016;12(2):136–66.Google Scholar
Bonnot, O, Cohen, D, Thuilleaux, D, Consoli, A, Cabal, S, Tauber, M. Psychotropic treatments in Prader-Willi syndrome: A critical review of published literature. Eur J Pediatr 2016;175(1):9–18.Google Scholar
Duma, SR, Fung, VS. Drug-induced movement disorders. Aust Prescr 2019;42(2):56–61.CrossRefGoogle ScholarPubMed
Akça, ÖF, Yilmaz, S. Aripiprazole in the treatment of obsessive compulsive disorder and aggressive behaviors in a child with Prader-Willi syndrome: A case report. J Clin Psychopharmacol 2016;36(5):526–8.Google Scholar
Cohen, D, Raffin, M, Canitano, R, Bodeau, N, Bonnot, O, Périsse, D, et al. Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord 2013;7(1):167–75.Google Scholar
Lloret-Linares, C, Faucher, P, Coupaye, M, Alili, R, Green, A, Basdevant, A, et al. Comparison of body composition, basal metabolic rate and metabolic outcomes of adults with Prader Willi syndrome or lesional hypothalamic disease, with primary obesity. Int J Obes (Lond) 2013;37(9):1198–203.Google Scholar
Solmi, M, Murru, A, Pacchiarotti, I, Undurraga, J, Veronese, N, Fornaro, M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: A state-of-the-art clinical review. Ther Clin Risk Manag 2017;13:757–77.Google Scholar
Schooler, NR, Kane, JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39(4):486–7.Google Scholar
Artukoglu, BB, Li, F, Szejko, N, Bloch, MH. Pharmacologic treatment of tardive dyskinesia: A meta-analysis and systematic review. J Clin Psychiatry 2020;81(4):19r12798. doi: 10.4088/JCP.19r12798Google Scholar
Arya, D, Khan, T, Margolius, AJ, Fernandez, HH. Tardive dyskinesia: Treatment update. Curr Neurol Neurosci Rep 2019;19(9):69.Google Scholar
Grundy, SM, Cleeman, JI, Daniels, SR, Donato, KA, Eckel, RH, Franklin, BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112(17):2735–52.Google Scholar
Wit, JM, Hero, M, Nunez, SB. Aromatase inhibitors in pediatrics. Nat Rev Endocrinol 2011;8(3):135–47.Google ScholarPubMed
Yeager, A, Shad, MU. Aripiprazole for the management of antipsychotic-induced hyperprolactinemia: A retrospective case series. Prim Care Companion CNS Disord 2020;22(1):19br02536. doi: 10.4088/PCC.19br02536CrossRefGoogle ScholarPubMed
Pileggi, DJ, Cook, AM. Neuroleptic malignant syndrome. Ann Pharmacother 2016;50(11):973–81.Google Scholar
Thase, ME. Recognition and diagnosis of atypical depression. J Clin Psychiatry 2007;68 Suppl 8:11–6.Google Scholar
Leverich, GS, Altshuler, LL, Frye, MA, Suppes, T, McElroy, SL, Keck, PE, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163(2):232–9.Google Scholar
Foley, KF, DeSanty, KP, Kast, RE. Bupropion: Pharmacology and therapeutic applications. Expert Rev Neurother 2006;6(9):1249–65.Google Scholar
Khera, R, Murad, MH, Chandar, AK, Dulai, PS, Wang, Z, Prokop, LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA 2016;315(22):2424–34.Google Scholar
FDA antidepressant suicidality [Internet]. [cited June 22, 2021]. Available from www.fda.gov/media/77404/downloadGoogle Scholar
Woroń, J, Siwek, M. Unwanted effects of psychotropic drug interactions with medicinal products and diet supplements containing plant extracts. Psychiatr Pol 2018;52(6):983–96.CrossRefGoogle ScholarPubMed
Wang, RZ, Vashistha, V, Kaur, S, Houchens, NW. Serotonin syndrome: Preventing, recognizing, and treating it. Cleve Clin J Med 2016;83(11):810–17.CrossRefGoogle Scholar
Deest, M, Jakob, MM, Seifert, J, Bleich, S, Frieling, H, Eberlein, C. Sertraline as a treatment option for temper outbursts in Prader-Willi syndrome. Am J Med Genet A 2021;185(3):790–7.Google Scholar
FDA valproate [Internet]. [cited June 22, 2021]. Available from www.accessdata.fda.gov/drugsatfda_docs/label/2009/018723s039lbl.pdfGoogle Scholar
Grant, JE, Odlaug, BL, Kim, SW. Lamotrigine treatment of pathologic skin picking: An open-label study. J Clin Psychiatry 2007;68(9):1384–91.CrossRefGoogle ScholarPubMed
Sani, G, Gualtieri, I, Paolini, M, Bonanni, L, Spinazzola, E, Maggiora, M, et al. Drug treatment of trichotillomania (hair-pulling disorder), excoriation (skin-picking) disorder, and nail-biting (onychophagia). Curr Neuropharmacol 2019;17(8):775–86.CrossRefGoogle ScholarPubMed
Gidal, BE, Sheth, R, Parnell, J, Maloney, K, Sale, M. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: Implications for conversion to lamotrigine monotherapy. Epilepsy Res 2003;57(2–3):85–93.Google Scholar
Perucca, E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61(3):246–55.Google Scholar
Mooney, LN, Dominick, KC, Erickson, CA. Psychopharmacology of neurobehavioral disorders. Handb Clin Neurol 2019;165:383–90.CrossRefGoogle ScholarPubMed
East, N, Maroney, M. Topiramate in the treatment of Prader-Willi syndrome: A case report. Ment Health Clin 2017;7(1):7–9.CrossRefGoogle ScholarPubMed
Consoli, A, Çabal Berthoumieu, S, Raffin, M, Thuilleaux, D, Poitou, C, Coupaye, M, et al. Effect of topiramate on eating behaviours in Prader-Willi syndrome: TOPRADER double-blind randomised placebo-controlled study. Transl Psychiatry 2019;9(1):274.CrossRefGoogle ScholarPubMed
Robertson, K, Marshman, LAG, Plummer, D, Downs, E. Effect of gabapentin vs pregabalin on pain intensity in adults with chronic sciatica: A randomized clinical trial. JAMA Neurol 2019;76(1):28–34.CrossRefGoogle ScholarPubMed
Houghton, KT, Forrest, A, Awad, A, Atkinson, LZ, Stockton, S, Harrison, PJ, et al. Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: Protocol for a systematic review and meta-analysis. BMJ Open 2017;7(3):e013433.Google Scholar
Butler, MG, Miller, JL, Forster, JL. Prader-Willi syndrome: Clinical genetics, diagnosis and treatment approaches: An update. Curr Pediatr Rev 2019;15(4):207–44.CrossRefGoogle ScholarPubMed
McGoldrick, MK, Galanopoulou, AS. Developmental pharmacology of benzodiazepines under normal and pathological conditions. Epileptic Disord 2014;16 Spec No 1:S59–S68.Google Scholar
Kang, M, Galuska, MA, Ghassemzadeh, S. Benzodiazepine Toxicity. Treasure Island, FL: StatPearls, 2021.Google Scholar
Fluyau, D, Revadigar, N, Manobianco, BE. Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Ther Adv Psychopharmacol 2018;8(5):147–68.CrossRefGoogle ScholarPubMed
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5).Google Scholar
Kalachnik, JE, Hanzel, TE, Sevenich, R, Harder, SR. Benzodiazepine behavioral side effects: Review and implications for individuals with mental retardation. Am J Ment Retard 2002;107(5):376–410.2.0.CO;2>CrossRefGoogle ScholarPubMed
Schulz, KP, Clerkin, SM, Fan, J, Halperin, JM, Newcorn, JH. Guanfacine modulates the influence of emotional cues on prefrontal cortex activation for cognitive control. Psychopharmacology (Berl) 2013;226(2):261–71.CrossRefGoogle ScholarPubMed
Drugs@FDA: FDA–approved drugs [Internet]. [cited June 21, 2021]. Available from www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=200881Google Scholar
Pringsheim, T, Hirsch, L, Gardner, D, Gorman, DA. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: A systematic review and meta-analysis. Part 1: Psychostimulants, alpha-2 agonists, and atomoxetine. Can J Psychiatry 2015;60(2):42–51.Google Scholar
Scahill, L, McCracken, JT, King, BH, Rockhill, C, Shah, B, Politte, L, et al. Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry 2015;172(12):1197–206.Google Scholar
Davis, NO, Kollins, SH. Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder. Neurotherapeutics 2012;9(3):518–30.CrossRefGoogle ScholarPubMed
Singh, D, Wakimoto, Y, Filangieri, C, Pinkhasov, A, Angulo, M. Guanfacine extended release for the reduction of aggression, attention-deficit/hyperactivity disorder symptoms, and self-injurious behavior in Prader-Willi syndrome: A retrospective cohort study. J Child Adolesc Psychopharmacol 2019;29(4):313–17.CrossRefGoogle ScholarPubMed
Guanfacine for the reduction of aggressive & self-injurious behaviors [Internet]. [June 22, 2021]. Available from www.fpwr.org/clinical-trials/guanfacineGoogle Scholar
Carney, MW. Diethylpropion and psychosis. Clin Neuropharmacol 1988;11(2):183–8.Google Scholar
Moran, LV, Ongur, D, Hsu, J, Castro, VM, Perlis, RH, Schneeweiss, S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380(12):1128–38.Google Scholar
Pullen, LC, Picone, M, Tan, L, Johnston, C, Stark, H. Cognitive improvements in children with Prader-Willi syndrome following pitolisant treatment: Patient reports. J Pediatr Pharmacol Ther 2019;24(2):166–71.Google Scholar
Pfeffer, CR, Jiang, H, Domeshek, LJ. Buspirone treatment of psychiatrically hospitalized prepubertal children with symptoms of anxiety and moderately severe aggression. J Child Adolesc Psychopharmacol 1997;7(3):145–55.Google Scholar
Tauber, M, Mantoulan, C, Copet, P, Jauregui, J, Demeer, G, Diene, G, et al. Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: A randomised placebo-controlled trial in 24 patients. Orphanet J Rare Dis 2011;6:47.Google Scholar
Miller, JL, Tamura, R, Butler, MG, Kimonis, V, Sulsona, C, Gold, J-A, et al. Oxytocin treatment in children with Prader-Willi syndrome: A double-blind, placebo-controlled, crossover study. Am J Med Genet A 2017;173(5):1243–50.Google Scholar
Einfeld, SL, Smith, E, McGregor, IS, Steinbeck, K, Taffe, J, Rice, LJ, et al. A double-blind randomized controlled trial of oxytocin nasal spray in Prader-Willi syndrome. Am J Med Genet A 2014;164A(9):2232–9.Google Scholar
Dykens, EM, Miller, J, Angulo, M, Roof, E, Reidy, M, Hatoum, HT, et al. Intranasal carbetocin reduces hyperphagia in individuals with Prader-Willi syndrome. JCI Insight 2018;3(12):e98333. doi: 10.1172/jci.insight.98333CrossRefGoogle ScholarPubMed
Kwan Cheung, KA, Mitchell, MD, Heussler, HS. Cannabidiol and neurodevelopmental disorders in children. Front Psychiatry 2021;12:643442.Google Scholar
Nguyen, T, Thomas, BF, Zhang, Y. Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: Current approaches for therapeutics development. Curr Top Med Chem 2019;19(16):1418–35.CrossRefGoogle ScholarPubMed
Soni, S, Whittington, J, Holland, AJ, Webb, T, Maina, E, Boer, H, et al. The course and outcome of psychiatric illness in people with Prader-Willi syndrome: Implications for management and treatment. J Intellect Disabil Res 2007;51(Pt 1):32–42.CrossRefGoogle ScholarPubMed
Francescangeli, J, Karamchandani, K, Powell, M, Bonavia, A. The serotonin syndrome: From molecular mechanisms to clinical practice. Int J Mol Sci 2019;20(9):2288. doi: 10.3390/ijms20092288CrossRefGoogle ScholarPubMed
Eldar-Geva, T, Hirsch, HJ, Pollak, Y, Benarroch, F, Gross-Tsur, V. Management of hypogonadism in adolescent girls and adult women with Prader-Willi syndrome. Am J Med Genet A 2013;161A(12):3030–4.Google ScholarPubMed
Natural History Study of Serious Medical Events in PWS – Full Text View – ClinicalTrials.gov [Internet]. [cited June 25, 2021]. Available from clinicaltrials.gov/ct2/show/NCT03718416Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×